Clinical Pharmacology and Pharmacy, 2017 (vol. 31), issue 1
Original articles
Lipegfilgrastim, effective option how to avoid chemotherapy-induced neutropenia
Jana Ďurková
Klin Farmakol Farm. 2017;31(1):3-10 | DOI: 10.36290/far.2017.002 
Backround: Toxicity is an integral part of oncological treatment. Serious adverse effects of systemic therapy, which limits its administration is neutropenia. The risk of neutropenia is highly associated with a chemotherapy regimen used, but this risk is also affected by risk profile of patient. Complications of neutropenia are associated with increased morbidity, mortality and financial costs for supportive treatment. Curative intent or poor adherence of planned relative dose intensity (RDI) may adversely affect the overall treatment outcome. Material, methods: The article discusses the own experience on use of long-acting granulocyte colony stimulating...
Main topic
New hepatitis C therapy
Petr Husa, Petr Husa ml., Matúš Mihalčin
Klin Farmakol Farm. 2017;31(1):11-14 | DOI: 10.36290/far.2017.003
Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications and extraordinarilyfavorable safety profile. Current possibilities of interferon-free therapy represent combinations of sofosbuvir with otherDAA (ledipasvir, daclatasvir) or with ribavirin and combination of paritaprevir boosted by ritonavir + ombitasvir ± dasabuvir. Fixedcombinations of elbasvir and grazoprevir, and sofosbuvir + velpatasvir are already available in many countries of the world. Very probablenew fixed combinations sofosbuvir + velpatasvir + voxilaprevir, and glecaprevir + pibrentasvir...
Current opinion in epidemiology and approaches to the treatment of viral hepatitis A and E.
Matúš Mihalčin, Lenka Fašaneková, Petr Husa ml., Petr Husa
Klin Farmakol Farm. 2017;31(1):15-18 | DOI: 10.36290/far.2017.004
Viral hepatitis A and E share some epidemiological and clinical characteristics, thus are often associated as related diseases. Newdiscoveries in the last decade, particularly for hepatitis E, change the view on these diseases. The review describes the specificsof each disease and current possibilities of pharmacological intervention on the clinical course of the disease caused by hepatitisA virus (HAV) and hepatitis E virus (HEV).
Alveolar echinococcosis – life-threatening disease
Petr Husa ml., Matúš Mihalčin, Petr Husa
Klin Farmakol Farm. 2017;31(1):19-21 | DOI: 10.36290/far.2017.005
Alveolar echinococcosis (AE) is serious parasitic disease imitating malignant tumors with its appearance and growth. AE is caused by small tapeworm called Echinococcus multilocularis (EM) with is living in gastrointestinal tract of carnivores. Early diagnostic and radical surgical excision in combination with long-term chemotherapy may completely eradicate the parasites and cure the patient. Untreated disease has mortality rate more than 90 % within 10–15 years. Echinococcosis is very rare disease in the Czech Republic. Only few cases are diagnosed each year. However with increasing distribution and prevalence of EM in European population of...
Review articles
Anti-inflammatory treatment of stable COPD – current trends and recommendations for clinical practice
Experts statement
Štefan Laššán, Marta Hájková, Monika Laššánová
Klin Farmakol Farm. 2017;31(1):22-30 | DOI: 10.36290/far.2017.006
Chronic obstructive pulmonary disease (COPD) is a chronic, complex and heterogeneous lung disease with increasingmorbidity and mortality worldwide. Inhaled bronchodilators, long-acting muscarinic receptor antagonists (LAMAs) andlong-acting beta2-agonists (LABAs), are the most common and important drugs used for the treatment of COPD. In individualswith persistent symptoms or frequent exacerbations anti-inflammatory drugs (inhaled corticosteroids, selective inhibitor of theenzyme phosphodiesterase-4, some antibiotics, mucolytic and antioxidant drug) are also used. In the field of personalized medicine,it’s important...
Secukinumab in treating psoriatic arthritis
Hana Ciferská, Jiří Štolfa
Klin Farmakol Farm. 2017;31(1):31-36 | DOI: 10.36290/far.2017.007
Psoriatic arthritis (PsA) is a chronic autoimmune inflammatory disease manifested by involvement of the musculoskeletal system and skin. The manifestations of PsA tend to significantly negatively affect the quality of life of patients, ranging from common self-care tasks to the psychological-social domain. The introduction of biological therapy has brought substantial improvement in the prognosis of patients not responding to conventional treatment. The success of affecting the tumour necrosis factor α with therapeutic monoclonal antibodies has been followed by extensive research into other potentially suitable molecules. Secukinumab has become...
Cilostazol in treating lower limb ischaemia
Dalibor Musil
Klin Farmakol Farm. 2017;31(1):37-39 | DOI: 10.36290/far.2017.030
Cilostazol is a vasodilator with antiplatelet and metabolic properties. In addition to physical activity, it is used in the treatment ofintermittent claudications, i. e. classic clinical signs of chronic limb ischaemia. Professional societies’ guidelines list it as the firstdrug of choice. While the effect of cilostazol on claudications has been evaluated in a number of studies, its options for affectingthe individual cardiovascular and cerebrovascular risks still remain unappreciated.
Case reports
Experience from the practice with “first-and-a-half” line biological therapy in patients with relapsing-remitting multiple sclerosis
Petr Pšenica
Klin Farmakol Farm. 2017;31(1):40-42 | DOI: 10.36290/far.2017.008
A change in the reimbursement decree has enabled early escalation to the so-called first-and-a-half line drugs, i. e. fingolimod anddimethyl fumarate, in patients with relapsing-remitting multiple sclerosis following one moderate or severe attack. We presenta case of a female patient in whom early escalation was possible after having met the new reimbursement criteria.